WEKO3
アイテム
{"_buckets": {"deposit": "6ab9fcac-e9b8-4f18-a3e5-f46f41f5666d"}, "_deposit": {"created_by": 11, "id": "4115", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "4115"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00004115", "sets": ["221"]}, "author_link": ["7969", "8851", "8845", "8847", "8848", "8850", "8846", "538", "8849", "8844"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "73", "bibliographicPageStart": "65", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{}, {"bibliographic_title": "Journal of diabetes investigation", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "前川, 聡"}], "nameIdentifiers": [{"nameIdentifier": "538", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00209363", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=00209363"}, {"nameIdentifier": "0000-0002-4611-8149", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0002-4611-8149"}]}]}, "item_4_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "pdf", "subitem_description_type": "Other"}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aims/Introduction:\nType 2 diabetes mellitus is caused by a relative imbalance between insulin secretion and sensitivity related to the body mass index (BMI). Seven categories of oral antidiabetic drugs (OADs) are available in Japan. It is important to assess the OAD utilization patterns based on patients’ BMI levels.", "subitem_description_type": "Abstract"}, {"subitem_description": "Materials and methods:\nOAD prescribing patterns from 2002 to 2019 were analyzed using the data collected in the computerized diabetes care database provided by the Japan Diabetes Clinical Data Management Study Group; OAD utilization patterns in 25,751 OAD-treated type 2 diabetes mellitus patients registered in 2019 were analyzed after classifying them into five categories of BMI.", "subitem_description_type": "Abstract"}, {"subitem_description": "Results:\nComparing OAD usage between 2002 and 2019, sulfonylureas decreased from 44.5 to 23.2%, and biguanides (BGs) increased from 19.3 to 50.3%. Dipeptidyl peptidase-4 inhibitors (DPP4is) increased to 56.9% in 2019. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) increased to 23.6% in 2019. About 90% of type 2 diabetes mellitus patients had BMI \u003c 30 kg/m2 . DPP4is were the most used OADs in 2019. When BMI exceeded 30 kg/m2 , use of BGs and sodium-glucose cotransporter 2 inhibitors increased, and use of sulfonylureas and DPP4is decreased. Although DPP4is were the most used OADs for patients with BMI \u003c30 kg/m2 , they were the third most prescribed OADs for patients with BMI \u003e35 kg/m2 after BGs and sodium-glucose cotransporter 2 inhibitors . ", "subitem_description_type": "Abstract"}, {"subitem_description": "Conclusions:\nDPP4i usage was as high as that of BG in the analysis of Japanese type 2 diabetes mellitus patients with relatively low BMI. This was considered to be a treatment option appropriate for the pathophysiology in Japanese patients.", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley"}]}, "item_4_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "34191401", "subitem_relation_type_select": "PMID"}}]}, "item_4_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1111/jdi.13621"}], "subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/jdi.13621", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_13": {"attribute_name": "PMCID", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "PMC8756302"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8756302/", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley \u0026 Sons Australia, Ltd."}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2040-1124", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "YAGI, Noriharu"}], "nameIdentifiers": [{"nameIdentifier": "8844", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KOMIYA, Ichiro"}], "nameIdentifiers": [{"nameIdentifier": "8845", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ARAI, Keiko"}], "nameIdentifiers": [{"nameIdentifier": "8846", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OISHI, Mariko"}], "nameIdentifiers": [{"nameIdentifier": "8847", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUKUMOTO, Yoshihide"}], "nameIdentifiers": [{"nameIdentifier": "8848", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SHIRABE, Shunichirou"}], "nameIdentifiers": [{"nameIdentifier": "8849", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YOKOYAMA, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "7969", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAMAZAKI, Katsuya"}], "nameIdentifiers": [{"nameIdentifier": "8850", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SUGIMOTO, Hidekatsu"}], "nameIdentifiers": [{"nameIdentifier": "8851", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MAEGAWA, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "538", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00209363", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=00209363"}, {"nameIdentifier": "0000-0002-4611-8149", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0002-4611-8149"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-02-09"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "jdi.13621.pdf", "filesize": [{"value": "581.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.", "licensetype": "license_free", "mimetype": "application/pdf", "size": 581700.0, "url": {"label": "jdi.13621", "url": "https://shiga-med.repo.nii.ac.jp/record/4115/files/jdi.13621.pdf"}, "version_id": "289c78fc-3470-4eba-83cf-f010f6dfdd6b"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antidiabetic drugs", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Body mass index", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Diabetes mellitus type 2", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists\u0027 prescribing patterns from 2002 to 2019 (JDDM61)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists\u0027 prescribing patterns from 2002 to 2019 (JDDM61)"}]}, "item_type_id": "4", "owner": "11", "path": ["221"], "permalink_uri": "http://hdl.handle.net/10422/00013208", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-02-09"}, "publish_date": "2022-02-09", "publish_status": "0", "recid": "4115", "relation": {}, "relation_version_is_last": true, "title": ["Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists\u0027 prescribing patterns from 2002 to 2019 (JDDM61)"], "weko_shared_id": -1}
Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61)
http://hdl.handle.net/10422/00013208
http://hdl.handle.net/10422/0001320884ec9a8f-f8c4-4fb5-95e5-80ac5da1c67f
名前 / ファイル | ライセンス | アクション |
---|---|---|
jdi.13621 (581.7 kB)
|
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-02-09 | |||||
タイトル | ||||||
タイトル | Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61) | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Antidiabetic drugs | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Body mass index | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Diabetes mellitus type 2 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
YAGI, Noriharu
× YAGI, Noriharu× KOMIYA, Ichiro× ARAI, Keiko× OISHI, Mariko× FUKUMOTO, Yoshihide× SHIRABE, Shunichirou× YOKOYAMA, Hiroki× YAMAZAKI, Katsuya× SUGIMOTO, Hidekatsu× MAEGAWA, Hiroshi |
|||||
著者別名 |
前川, 聡
× 前川, 聡 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aims/Introduction: Type 2 diabetes mellitus is caused by a relative imbalance between insulin secretion and sensitivity related to the body mass index (BMI). Seven categories of oral antidiabetic drugs (OADs) are available in Japan. It is important to assess the OAD utilization patterns based on patients’ BMI levels. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Materials and methods: OAD prescribing patterns from 2002 to 2019 were analyzed using the data collected in the computerized diabetes care database provided by the Japan Diabetes Clinical Data Management Study Group; OAD utilization patterns in 25,751 OAD-treated type 2 diabetes mellitus patients registered in 2019 were analyzed after classifying them into five categories of BMI. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Results: Comparing OAD usage between 2002 and 2019, sulfonylureas decreased from 44.5 to 23.2%, and biguanides (BGs) increased from 19.3 to 50.3%. Dipeptidyl peptidase-4 inhibitors (DPP4is) increased to 56.9% in 2019. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) increased to 23.6% in 2019. About 90% of type 2 diabetes mellitus patients had BMI < 30 kg/m2 . DPP4is were the most used OADs in 2019. When BMI exceeded 30 kg/m2 , use of BGs and sodium-glucose cotransporter 2 inhibitors increased, and use of sulfonylureas and DPP4is decreased. Although DPP4is were the most used OADs for patients with BMI <30 kg/m2 , they were the third most prescribed OADs for patients with BMI >35 kg/m2 after BGs and sodium-glucose cotransporter 2 inhibitors . |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Conclusions: DPP4i usage was as high as that of BG in the analysis of Japanese type 2 diabetes mellitus patients with relatively low BMI. This was considered to be a treatment option appropriate for the pathophysiology in Japanese patients. |
|||||
書誌情報 |
en : Journal of diabetes investigation 巻 13, 号 1, p. 65-73, 発行日 2022-01 |
|||||
出版者 | ||||||
出版者 | Wiley | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2040-1124 | |||||
PMID | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 34191401 | |||||
PMCID | ||||||
識別子タイプ | URI | |||||
関連識別子 | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8756302/ | |||||
関連名称 | PMC8756302 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1111/jdi.13621 | |||||
関連名称 | 10.1111/jdi.13621 | |||||
権利 | ||||||
権利情報 | © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | ||||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article |